Researchers and medical professionals will meet this week in Europe to try and get some answers about a potential link between cancer and a top diabetes medication that came to the forefront earlier this summer, according to a recent article published by Bloomberg.
Diabetes and cancer have been linked in a number of recent news article, both for good and potentially bad reasons. While a number of drugs have been shows to lower the risk of certain types of cancer and even be used as a potential cure in the future for others, some scary data surfaced in June when researchers said Lantus, one of the world’s most popular insulin treatments, may increase the risk of cancer.
Lantus, which is made by Sanofi-Aventis, is an insulin analogue that is generally injected once a day with the goal of helping to keep blood-sugar levels in check in between meals and overnight. Additionally, U.S. regulators delayed ruling on Novo Nordisk’s liraglutide drug after some testing of the drug on animals showed cases of thyroid cancer.
The recent research has led many in the medical community wondering whether they need to pay closer attention to the risk versus reward of these types of drugs. Both Sanofi-Aventis and Novo Nordisk will prevent safety info about Lantus and Levemir at this year’s European Association for the Study of Diabetes on Oct. 1.
To receive free news updates from Diabetes News Hound delivered straight to your Inbox, sign up here. If you already receive the free Alerts, spread the word by telling a friend to sign up here.
